AZIYO BIOLOGICS(AZYO) - 2025 Q3 - Quarterly Results

Financial Performance - Overall net sales for Q3 2025 were $3.3 million, a decrease from $3.7 million in Q3 2024, excluding contributions from the BioEnvelope business[5] - Net sales of SimpliDerm were $2.4 million in Q3 2025, down from $3.1 million in Q3 2024[5] - Net sales for Q3 2025 were $3,323 million, a decrease of 9.2% compared to $3,662 million in Q3 2024[17] - The net loss for Q3 2025 was $3,868 million, compared to a net income of $1,286 million in Q3 2024[20] - Elutia's adjusted EBITDA for Q3 2025 was a loss of $2.7 million, approximately the same as the previous year[10] - Adjusted EBITDA for Q3 2025 was $(2,742) million, slightly worse than $(2,682) million in Q3 2024[20] Cost Management and Expenses - Total operating expenses decreased to $7.1 million in Q3 2025, down from $11.0 million in the same period last year[10] - Total operating expenses for Q3 2025 were $7,061 million, down from $10,966 million in Q3 2024, primarily due to reduced litigation costs[17] - Research and development expenses increased to $1,088 million in Q3 2025 from $702 million in Q3 2024, reflecting a focus on innovation[17] Profitability Metrics - Gross margin on a GAAP basis improved to 55.8% in Q3 2025, compared to 48.9% in Q3 2024[10] - Gross profit for Q3 2025 was $1,853 million, representing a gross margin of 55.8%, up from 48.9% in Q3 2024[18] - The adjusted gross profit for Q3 2025 was $2,122 million, with an adjusted gross margin of 63.9%, up from 56.3% in Q3 2024[18] Strategic Actions - Elutia sold its BioEnvelope business to Boston Scientific Corporation for $88 million, with proceeds used to eliminate debt and fund the NXT-41x development program[4] - The anticipated FDA clearance for the base matrix of NXT-41x is expected in the second half of 2026, with the drug-eluting version expected in the first half of 2027[4] - The company has resolved a significant portion of its legacy litigation, leaving only six cases unresolved, which is expected to reduce future litigation expenses[4] - The company anticipates continued focus on cost management and strategic investments in R&D to drive future growth[21] Operational Losses - Loss from operations was $5.2 million in Q3 2025, an improvement from a loss of $9.2 million in Q3 2024[10] - The company reported a loss from discontinued operations of $3,485 million in Q3 2025, compared to $2,053 million in Q3 2024[20] Shareholder Information - The weighted average common shares outstanding for basic shares increased to 42,431,314 in Q3 2025 from 32,520,134 in Q3 2024[17]